Literature DB >> 7831439

Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia.

T Hashimoto1, N Kitamura, Y Kajimoto, Y Shirai, O Shirakawa, T Mita, N Nishino, C Tanaka.   

Abstract

Serotonin 5-HT1A and 5-HT2 receptors were examined in the postmortem brains of controls and patients with chronic schizophrenia. In the prefrontal cortex from patients with schizophrenia, 5-HT1A receptor binding was increased, while 5-HT2 receptor binding was decreased, when compared to controls. The increased 5-HT1A receptor binding or the decreased 5-HT2 receptor binding was observed in both the patients who had been medicated with neuroleptics at time of death and those who had not, at least 2 months prior to death. Thus, abnormalities of 5-HT receptor subtypes seem to exist in the brains of patients with chronic schizophrenia. 5-HT related agents might be beneficial for the treatment of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7831439     DOI: 10.1007/bf02245005

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

1.  Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients.

Authors:  R C Arora; H Y Meltzer
Journal:  J Neural Transm Gen Sect       Date:  1991

2.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

3.  Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding.

Authors:  M Pompeiano; J M Palacios; G Mengod
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

Review 4.  Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system.

Authors:  E C Azmitia; P M Whitaker-Azmitia
Journal:  J Clin Psychiatry       Date:  1991-12       Impact factor: 4.384

5.  Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT.

Authors:  H Gozlan; S El Mestikawy; L Pichat; J Glowinski; M Hamon
Journal:  Nature       Date:  1983 Sep 8-14       Impact factor: 49.962

6.  Depletion of brain serotonin differently affects behaviors induced by 5HT1A, 5HT1C, and 5HT2 receptor activation in rats.

Authors:  H H Berendsen; C L Broekkamp; A M van Delft
Journal:  Behav Neural Biol       Date:  1991-03

Review 7.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.

Authors:  H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Increased dopamine-receptor sensitivity in schizophrenia.

Authors:  F Owen; A J Cross; T J Crow; A Longden; M Poulter; G J Riley
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

9.  Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI.

Authors:  J Arnt; J Hyttel
Journal:  Eur J Pharmacol       Date:  1989-02-14       Impact factor: 4.432

10.  Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites.

Authors:  D Hoyer; A Pazos; A Probst; J M Palacios
Journal:  Brain Res       Date:  1986-06-18       Impact factor: 3.252

View more
  9 in total

1.  Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats.

Authors:  Yong Kee Choi; Taylor Moran-Gates; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2009-10-29       Impact factor: 4.600

Review 2.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling.

Authors:  S I Rapoport
Journal:  J Mol Neurosci       Date:  2001 Apr-Jun       Impact factor: 3.444

4.  Changes in protein kinase C and adenylate cyclase in the temporal lobe from subjects with schizophrenia.

Authors:  B Dean; K Opeskin; G Pavey; C Hill; N Keks
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

5.  Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine.

Authors:  L Naylor; B Dean; K Opeskin; G Pavey; C Hill; N Keks; D Copolov
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 6.  Management of the negative symptoms of schizophrenia: new treatment options.

Authors:  Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia.

Authors:  D C Goff; K K Midha; O Sarid-Segal; J W Hubbard; E Amico
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

8.  Relationship between genetic polymorphisms in the HTR1A gene and paranoid schizophrenia in a northern Han Chinese population.

Authors:  Xue Zhou; Mei Ding; Chunli Ding; Jun Yao; Hao Pang; Jiaxin Xing; Jinfeng Xuan; Baojie Wang
Journal:  J Mol Neurosci       Date:  2012-11-29       Impact factor: 3.444

9.  The loudness dependence of auditory evoked potentials (LDAEP) as an indicator of serotonergic dysfunction in patients with predominant schizophrenic negative symptoms.

Authors:  Christine Wyss; Konrad Hitz; Michael P Hengartner; Anastasia Theodoridou; Caitriona Obermann; Idun Uhl; Patrik Roser; Edna Grünblatt; Erich Seifritz; Georg Juckel; Wolfram Kawohl
Journal:  PLoS One       Date:  2013-07-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.